We further verified this amplification with the tissue sample at time of progression on entrectinib and sotorasib by FISH which demonstrated a KRAS/CEP12 ratio of 11.5 and uniform ROS1 positivity across tumor cells (Fig. 3b). The gene discussed is KRAS; the disease is neoplasm.